40 citations
,
December 2016 in “Journal of Dermatological Treatment” JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
June 2025 in “British Journal of Dermatology” JAK inhibitors help regrow hair in alopecia areata, but their long-term safety is still unclear.
116 citations
,
February 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors help with skin conditions but need more research on dosing and safety.
56 citations
,
January 2019 in “Lancet” JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
37 citations
,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
16 citations
,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
11 citations
,
April 2015 in “EBioMedicine” JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
9 citations
,
January 2023 in “Dermatology and therapy” A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
4 citations
,
May 2025 in “Frontiers in Immunology” JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.
1 citations
,
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
1 citations
,
September 2024 in “IP Indian Journal of Clinical and Experimental Dermatology” Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.
1 citations
,
September 2022 in “Sudan Journal of Medical Sciences” Danoprevir, remdesivir, and saridegib may effectively inhibit SARS-CoV-2.
1 citations
,
June 2021 in “Journal of dermatology and dermatitis” Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
March 2026 in “Frontiers in Medicine” New therapies for rare skin diseases show promise but need more research.
March 2026 in “Scientific Reports” Ferulic acid may help hair grow by activating certain receptors in cells.
Including ineffective or unsafe doses in reviews can lead to misleading conclusions about alopecia areata treatments.
Dupilumab may cause hair loss, so patients should be monitored.
August 2024 in “New Zealand Medical Student Journal” JAK inhibitors show promise for treating skin diseases effectively and safely.
September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)” The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
August 2023 in “Journal of inflammation research” An elderly Chinese man lost all his hair after taking a new heart medication.
Combining epinephrine with a steroid may help regrow hair in severe alopecia areata cases.
February 2026 in “Dove Medical Press (Taylor and Francis Group)” Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.
November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
July 2025 in “The Journal of Dermatology” Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
2 citations
,
January 2020 in “Einstein (São Paulo)” Topical tofacitinib shows promise as a future treatment for alopecia areata.
November 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.